I would be a little surprised if DrJ et al have not already thought about and come to their own conclusions about the mice and their liver cancer status at trial end. I think it’s a muddied situation to stir the cancer pot in the MASH mice trial and they will keep it clean and on point. These are not humans, who if they have liver cancer are in frequent contact with their oncologist and evaluated with frequent imaging studies to stage and monitor progression. For the mice I suspect they are not running them through a scanner or anything on an interim basis, it likely comes down to histologic liver evaluation with cytology at the end when any survivors are euthanized to study those endpoints…

It’s probably best to let the MSS CRC study…in humans…stand in as the voice for cancer impact.